Rayner Surgical Group
Rayner Surgical Group is a British medical device manufacturer that produces intraocular lenses, the Sophi phacoemulsification system, ophthalmic pharmaceuticals, and AI-enabled patient engagement platforms for ophthalmic clinics, hospitals, and cataract surgeons across 80+ countries.
- Company typePrivate
- Founded1910
- HeadquartersWorthing, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Rayner Surgical Group does
Rayner Surgical Group is a British medical device manufacturer specializing in ophthalmic solutions for cataract and refractive surgery, founded in 1949 when Sir Harold Ridley implanted the world's first intraocular lens (IOL). The company manufactures a complete cataract surgery portfolio from its Worthing, West Sussex headquarters — the only IOL manufacturing facility in the UK — including the RayOne family of IOLs (EMV extended range of focus, Trifocal, Monofocal, Toric) and the RayOne preloaded injector, the Sophi wireless phacoemulsification system (acquired from Swiss startup This AG in January 2024), the OMIDRIA intraocular pharmaceutical (phenylephrine/ketorolac), ophthalmic viscosurgical devices, and the AEON artificial tears line. It produces over 1 million IOLs annually and has shipped 400,000+ RayOne EMV lenses to more than 65 countries.
Rayner monetizes primarily through direct and distributor-led hardware sales of IOLs and capital equipment to ophthalmic clinics, hospitals, and cataract surgeons across 80+ countries, with direct sales offices in 15+ markets (UK, USA, Canada, Germany, Austria, France, Italy, Spain, Portugal, Poland, Australia, India, Brazil, Switzerland, Ireland). A growing recurring revenue layer is being built through the RayPRO patient-reported outcomes platform and the eyejourney AI-based patient engagement and consent platform (developed by its Innoptix digital arm), priced at $2,800-$9,000 per clinic on multi-year subscriptions. The company is privately held under CVC Capital Partners and GBL (which took a 45% stake for €500M in February 2026), employs 950+ people globally, and is expanding internationally through both organic launches and bolt-on acquisitions.
Rayner Surgical Group firmographics
Firmographics- Name
- Rayner Surgical Group
- Legal name
- Rayner Surgical Group Limited
- Website
- http://www.rayner.com/
- Company type
- Private
- Founded year
- 1910
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Rayner Surgical Group is a British medical device manufacturer that produces intraocular lenses, the Sophi phacoemulsification system, ophthalmic pharmaceuticals, and AI-enabled patient engagement platforms for ophthalmic clinics, hospitals, and cataract surgeons across 80+ countries.
- Ownership category
- akta.pro rank
Rayner Surgical Group industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH)
Keywords
Where Rayner Surgical Group is headquartered
LocationHeadquarters
- HQ city
- Worthing
- HQ country
- United Kingdom
- HQ region
- Europe
Offices16 records
Markets served
Rayner Surgical Group business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Intraocular Lenses (IOLs): Sale of intraocular lenses including RayOne family (EMV, Monofocal, Trifocal, Toric), supplementary lenses, and Galaxy preloaded injector system. Products sold directly and through distributors globally.
- Sophi Phacoemulsification System: Capital equipment sales including the Sophi wireless phaco system for cataract surgery, along with consumables.
- OMIDRIA Pharmaceutical: Sale of OMIDRIA ophthalmic pharmaceutical product for use during cataract surgery.
- Digital Platform Subscriptions: eyejourney AI platform with clinic pricing ranging from $2,800 to $9,000 depending on setup plans.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | eyejourney AI Platform - Clinic subscription pricing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Rayner Surgical Group product offering
Product offeringCore offering
Rayner Surgical Group manufactures and sells intraocular lenses (IOLs) including the RayOne family (EMV, Trifocal, Monofocal, Toric), the Sophi wireless phacoemulsification system for cataract surgery, the OMIDRIA ophthalmic pharmaceutical for use during cataract procedures, and digital platforms (RayPRO and eyejourney AI platform) that support ophthalmic clinics and surgeons.
Product overview
Rayner Surgical Group is a British medical device manufacturer specializing in ophthalmic solutions with over 70 years of history. The company operates a diversified portfolio organized around surgical devices, pharmaceuticals, and digital platforms. The core product lines include the RayOne family of intraocular lenses (IOLs) - spanning RayOne EMV (extended range of focus), RayOne Trifocal, RayOne Monofocal, and the RayOne Injector system - representing the company's flagship surgical device offerings. The Sophi Phacoemulsification System, acquired from Swiss company This AG in 2024, provides advanced wireless phaco technology for cataract surgery. The pharmaceutical portfolio centers on OMIDRIA, an intraocular solution for pupil dilation and pain reduction during surgery. Digital platforms include RayPRO for patient-reported outcomes collection over three years, and eyejourney, an AI-powered patient education and engagement platform developed by Rayner's Innoptix digital division. Additional offerings include OVDs (ophthalmic viscosurgical devices), artificial tears (AEON family), HASA contact lenses, and Raytrace biometry software. The company manufactures at its Worthing, UK facility and sells products in over 80 countries through distributors and direct sales offices.
Differentiator
Problem solved
Functional benefit
Brands
- RayOne: Family of intraocular lenses including EMV, Trifocal, Monofocal, and Toric variants, along with the RayOne Injector system.
- Sophi
- Omidria
- RayPro
- HASA Optix
- Innoptix
- Raytrace
- RayOne EMV
- Galaxy
- AEON
Products and services
- RayOne EMV Extended range of focus intraocular lens with patented non-diffractive optic profile using controlled positive spherical aberration, designed for cataract surgeons seeking monofocal-level contrast sensitivity with extended depth of focus.
- RayOne Trifocal Trifocal intraocular lens providing vision correction at distance, intermediate, and near ranges for cataract and refractive lens exchange patients.
- RayOne Monofocal Standard monofocal intraocular lens for cataract surgery providing single-distance vision correction.
- RayOne Injector Preloaded injector system for IOL delivery during cataract surgery, offering streamlined intraocular lens implantation.
- Sophi Phacoemulsification System Wireless battery-based phacoemulsification device for cataract surgery featuring a triple pump fluidics system designed to improve anterior chamber stability and surgical efficiency.
- OMIDRIA Intraocular solution containing phenylephrine and ketorolac for use during cataract surgery to maintain pupil dilation and reduce postoperative pain.
- RayPRO Free mobile and web-based digital platform that proactively collects Patient Reported Outcomes (PROs) over three years for RayOne IOL users.
- eyejourney AI Platform AI-based patient support and engagement platform for ophthalmic clinics featuring AI-generated videos with custom avatars, automated medication reminders, personalized messaging, and digital consent forms.
- OVDs (Ophthalmic Viscosurgical Devices) Ophthalmic viscosurgical devices used during cataract surgery to protect corneal endothelium and maintain space in the anterior chamber.
- AEON Family (Artificial Tears) Family of artificial tear products for eye care and dry eye treatment.
- Raytrace Biometry and calculation platform for intraocular lens power calculations supporting cataract and refractive surgery planning.
- Galaxy IOL System Intraocular lens system product line including preloaded injector options for cataract surgery.
- Duet Procedure (Sulcoflex Supplementary IOL) Supplementary IOL procedure combining Sulcoflex pseudophakic supplementary lens with primary IOL implantation for refractive enhancement.
Quantifiable outcome
- Up to 1.5D increased range of focus with emmetropic target
- +2 more outcomes
Companies that use Rayner Surgical Group
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Rayner Surgical Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Rayner Surgical Group partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- This AG (Swiss Ophthalmology Innovation)coreRayner acquired This AG, a Swiss startup that developed the wireless Sophi phaco device for eye surgery. This acquisition expanded Rayner's product portfolio in cataract surgery technology and led to FDA 510(k) clearance for the Sophi phacoemulsification system.
- Professor Graham BarrettcoreProfessor Graham Barrett collaborated with Rayner in developing the RayOne EMV increased range of focus IOL with patented non-diffractive optic profile.
- IMPACT Foundation BangladeshminorRayner has supported IMPACT Foundation Bangladesh for over 20 years through regular donations of intraocular lenses (100 lenses per month) for use on the Jibon Tari floating hospital, helping restore sight to some of the world's poorest people in Bangladesh.
- InnoptixcoreInnoptix is Rayner's digital arm that developed the eyejourney AI-based patient education and engagement platform for ophthalmic clinics.
- BSI (British Standards Institution)minorBSI Membership providing quality management system certification and standards compliance.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Rayner Surgical Group competitors and assessment
Company assessmentBroad incumbents
- Alcon: Alcon is the world's largest ophthalmic medical device company, offering a comprehensive cataract surgery portfolio including PanOptix trifocal IOLs, ORA intraoperative aberrometry, and Centurion phaco systems. It directly competes with Rayner across nearly every product category but at vastly greater scale.
- Johnson & Johnson Vision: J&J Vision is a major ophthalmic device player through its TECNIS IOL family (Symfony, Odyssey, Eyhance), CATALYS phaco system, and iFS advanced femtosecond laser. It competes head-to-head with Rayner in premium IOLs and is investing heavily in extended-depth-of-focus technology.
- Bausch + Lomb: Bausch + Lomb offers the enVista IOL family, Stellaris Elite phaco system, and a broad surgical product portfolio. It competes directly with Rayner across cataract surgery IOLs and equipment, particularly in North America and Europe.
Direct peers
- HOYA Corporation: HOYA Surgical Optics offers the Vivinex and iSert preloaded IOL systems, competing directly with Rayner in the monofocal and toric IOL segments across Europe and Asia-Pacific. Similar mid-sized scale to Rayner.
- Beaver-Visitec International (BVI): BVI Medical manufactures and distributes ophthalmic surgical instruments, viscoelastic devices, and IOLs (including the PODEYE and IC-8 Apthera IOLs). It competes directly with Rayner's OVDs, surgical consumables, and premium IOL portfolio.
- Carl Zeiss Meditec: Zeiss Meditec offers the CT LUCIA and AT ELANA IOL families, Callisto eye surgical assistance systems, and OPMI Lumera microscopes. It is a comparable mid-to-large competitor in premium IOLs and surgical workflow tools for cataract surgeons.
- STAAR Surgical: STAAR Surgical specializes in Implantable Collamer Lenses (ICLs) for refractive surgery and silicone IOLs. While smaller and more focused on refractive lens exchange, it competes with Rayner's premium vision correction portfolio.
Emerging players
- Ocular Therapeutix: Ocular Therapeutix develops sustained-release ocular drug delivery including Dextenza for post-surgical inflammation. It is an adjacent competitor to Rayner's OMIDRIA pharmaceutical offering used during cataract surgery.
- RxSight: RxSight pioneered the Light Adjustable Lens (LAL), the first IOL that enables post-operative power adjustments using UV light. It represents a disruptive technology that could compete with Rayner's RayOne EMV in the premium IOL upgrade market.
- Lenstec Inc: Lenstec is a smaller IOL manufacturer focused on premium refractive IOLs including the SBL-3 bifocal and ClearView 3 multifocal lenses. It competes in the same premium IOL niche as Rayner's RayOne Trifocal and EMV products.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
Rayner Surgical Group social profiles
Digital presenceRayner Surgical Group compliance and trust
Trust signalCompliance4 records
Rayner Surgical Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rayner Surgical Group leadership team
Management profileNumber of profiles
Profiles6 records
Rayner Surgical Group subsidiaries and ownership
Company hierarchySubsidiaries14 records
Rayner Surgical Group funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rayner Surgical Group M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rayner Surgical Group
What does Rayner Surgical Group do?
Rayner Surgical Group manufactures and sells intraocular lenses (IOLs) including the RayOne family (EMV, Trifocal, Monofocal, Toric), the Sophi wireless phacoemulsification system for cataract surgery, the OMIDRIA ophthalmic pharmaceutical for use during cataract procedures, and digital platforms (RayPRO and eyejourney AI platform) that support ophthalmic clinics and surgeons.
Is Rayner Surgical Group a public or private company?
Rayner Surgical Group is a private company. It is classified as private equity controlled and is currently operating.
When was Rayner Surgical Group founded?
Rayner Surgical Group was founded in 1910. It employs 251 to 500 people.
Where is Rayner Surgical Group based?
Rayner Surgical Group is headquartered in Worthing, United Kingdom, in the Europe region.
How does Rayner Surgical Group make money?
Four revenue lines are on record. Intraocular Lenses (IOLs) is the primary driver. The others are sophi Phacoemulsification System, OMIDRIA Pharmaceutical and digital Platform Subscriptions.
Who are Rayner Surgical Group's main competitors?
Broad incumbents on record are Alcon, Johnson & Johnson Vision and Bausch + Lomb. Direct peers are HOYA Corporation, Beaver-Visitec International (BVI), Carl Zeiss Meditec and STAAR Surgical. Emerging players are Ocular Therapeutix, RxSight and Lenstec Inc.
Does Rayner Surgical Group have an API?
No public API is recorded for Rayner Surgical Group.
What industry is Rayner Surgical Group in?
Rayner Surgical Group's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 3851.